Jennerex has initiated enrollment and the first patient has been randomized in a phase IIb clinical trial called TRAVERSE. The trial is evaluating the use of JX-594 to treat patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC), who failed prior therapy with sorafenib (NexavarR), the only approved drug for advanced HCC. In addition, Jennerex earned a milestone payment from its development and commercialization partner, Transgene, based on the randomization of the first patient in the TRAVERSE clinical trial.
The TRAVERSE phase IIb clinical trial is designed to enroll 120 patients with advanced liver cancer who have failed sorafenib therapy. The randomized study will be conducted at approximately 45 sites worldwide including North America, South Korea, Taiwan, Hong Kong, and Europe. The primary objective of the trial is to determine the overall survival benefit for patients receiving JX-594 with best supportive care, compared to best supportive care alone in patients with refractory advanced liver cancer.
